Moneycontrol
Get App
Last Updated : Nov 09, 2015 12:20 PM IST | Source: Moneycontrol.com

Sequent up 6%, gets approval from USFDA for Mangalore unit

In addition to USFDA, the site also approved by TGA (Australia), and WHO (Geneva) and has four CEPs for its APIs (EDQM) with more in pipeline.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Moneycontrol Bureau

Shares of Sequent Scientific gained 6.5 percent intraday Monday after its API Drug Manufacturing facility at Mangalore, Karnataka has received establishment inspection report (EIR) from United States Food and Drug Administration (USFDA).

This facility was inspected by the USFDA in June 2015 as part of compliance audit.

In addition to USFDA, the site also approved by TGA (Australia), and WHO (Geneva) and has four CEPs for its APIs (EDQM) with more in pipeline.

"The company has filed more than 30 drug master files covering USFDA, Europe, WHO, Australia, Canada with several more niche APIs in the pipeline for future filings," as per BSE release.

At 12:16 hrs Sequent Scientific was quoting at Rs 885, up Rs 6.75, or 0.77 percent on the BSE.

Posted by Rakesh Patil

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Nov 9, 2015 12:20 pm
Sections
Follow us on